Aduhelm controversy- part 2

No Gravatar

We spoke about the Aduhelm fiasco about two weeks ago.

But, the furor is not abating.  (FDA advisory committee members are complaining and resigning!)

While some patients are willing to swear by the drug and its utility, the proof of same is severely lacking.

We also have to consider that on three separate occasions the Peripheral and Central Nervous Systems Drug Advisory Committee voted to NOT approve the drug.  Yet, the FDA overrode these advisory committees (which is a very atypical result).  Moreover, the FDA initially provided NO logic or political reasoning as to why this drug was approved, despite the non-recommendations of the advisory committee. [We will have more about this tomorrow, when we present their response (and my editorial comments)!]

The FDA did not deny that the committee was correct in stating that the evidence that the drug lacked clinical proof of efficacy.  It just used a special approval process that is normally reserved for cancer trials and drugs-  the accelerated approval pathway- whereby drugs go to market before definitive proof exists of any clinical benefit.

The “logic” behind this approval process is not that the drug has a demonstrable effect on patient survival, well-being, or feeling.  No, this process is employed when the drug effects changes in the body in ways that might predict such a benefit.  (Aduhelm does bind to beta-amyloid structures, which are thought to create memory problems in Alzheimer’s patients when the amyloid binds to neurons in the patient’s brains.)

How Aducanumb works

But, there’s yet another problem with this approval.  Once a drug obtains FDA approval, Medicare is obliged to cover the cost of the medicine.  Given that Biogen plans to charge some $ 56000 a year for the therapy, we are not talking about chicken feed.

Nor does it help that the Institute of Clinical and Economic Review (ICER) argues against the price that Biogen has developed for the drug.  ICER believes the therapeutic value sets the price of the drug between $ 2500 and $ 8300 a year.  If Aduhelm achieved significantly higher success rates in patients, is would alter its recommended price levels at $ 11,100 to $ 23,100.  Those higher rates are still 1/3 to 1/6 what Biogen plans to charge.

Given that 1.2 -1.4 million patients are expected to be prescribed this drug, we are talking about a bonanza of some $ 73 billion for Biogen- all paid out at US Treasury expense.

So, it’s not just an FDA problem- it’s a Medicare problem.  One that requires Medicare have the ability to negotiate the prices  of drugs for which it pays- and to require any drug for which it pays to have all  clinical trials completed.

 

 

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
Share

23 thoughts on “Aduhelm controversy- part 2”

  1. So, a drug that has not been approved by the advisory committee and has not shown efficacy, has been approved by the FDA. At a minimal cost of $76 billion to taxpayers. Seriously, who are the people who approved it and have they been financially vetted?
    Victoria Juster recently posted..Love Never Dies

    1. The FDA is not responsible for monitoring costs- only the efficacy and safety of drugs. That’s a big enough mandate. One- that you will see as we read my blogs this week- they failed.
      Medicare needs to be empowered to negotiate drug prices- they already can negotiate hospital fees. It’s time they get these additional rights.

  2. I was wondering if you ever thought of changing the structure of your blog?
    Its very well written; I love what youve got to say. But maybe you could a little more
    in the way of content so people could connect with it better.

    Youve got an awful lot of text for only having one or two images.
    Maybe you could space it out better?
    delta 8 vape memphis recently posted..delta 8 vape memphis

    1. My forte is facts, data, and analysis. I am not an artist. I use images to better explain the facts presented- not to explain the concept by itself. So, one, two, or three images are often all it takes.

      But, thanks for your suggestion. I appreciate you point of view.

  3. I have learn some good stuff here. Certainly worth bookmarking for
    revisiting. I surprise how a lot attempt you put to make this
    type of wonderful informative site.

    best kratom recently posted..best kratom

  4. I blog frequently and I truly thank you for your content.
    This great article has truly peaked my interest. I am going to bookmark your site and keep
    checking for new information about once a week. I subscribed to your Feed as well.

    heraldnet.com recently posted..heraldnet.com

  5. I wanted to thank you for this fantastic read!!
    I absolutely enjoyed every little bit of it. I have got you
    book marked to check out new things you post…

    cbd for sale recently posted..cbd for sale

  6. These are really great ideas in on the topic of
    blogging. You have touched some good things here. Any way keep up wrinting.

    Latisha recently posted..Latisha

  7. Wonderful blog! I found it while searching on Yahoo News.
    Do you have any tips on how to get listed in Yahoo News?
    I’ve been trying for a while but I never seem to get there!
    Cheers

    https://www.heraldnet.com/marketplace/buy-weed-online-best-websites-to-order-recreational-marijuana/ recently posted..https://www.heraldnet.com/marketplace/buy-weed-online-best-websites-to-order-recreational-marijuana/

  8. Hi there! This is my first comment here so I just wanted to
    give a quick shout out and say I truly enjoy reading through
    your articles. Can you recommend any other blogs/websites/forums that go over the same topics?
    Appreciate it!
    cbd gummies for pain recently posted..cbd gummies for pain

Comments are closed.